Novo Nordisk A S
Wegovy HD
excess body weight
Resolved
110days ago
Approval decision · Mar 19, 2026
What's at stake
A final FDA approval decision on Wegovy HD for excess body weight is expected Mar 19, 2026.
Primary source
· SEC 6-K
verified 15h ago
“The FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.”